Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05958368 · ClinicalTrials.gov registry record · NA

Assessing the Value of Avocados on Glycemic Control in Type 2 Diabetes

A NA study of Diabetes Mellitus, Type 2 and Overweight and Obesity, sponsored by Pennington Biomedical Research Center.

Recruiting
Registry status
NA
Development phase
48
Enrollment target
1
Study location

NCT05958368 is a NA study of Diabetes Mellitus, Type 2 and Overweight and Obesity that is actively recruiting participants, run by Pennington Biomedical Research Center. The registered enrollment target is 48 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05958368, a NA study of Diabetes Mellitus, Type 2 and Overweight and Obesity, is actively recruiting participants, sponsored by Pennington Biomedical Research Center.

RECRUITING
Registry status
NA
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to assess the effects of Hass Avocados on glycemic control. The investigators hypothesize that Hass Avocado consumption will reduce fasting blood sugar compared to an isocaloric amount of other fruit during controlled feeding.

Interventions

  • OTHER Avocado
  • OTHER Other Fruit(s)

Study Locations (1)

Louisiana

  • Pennington Biomedical Research Center - Baton Rouge

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2023-10-10
Est. Completion 2026-12-15
Phase NA

What the Registry Record Tells You About NCT05958368

The ClinicalTrials.gov registry entry for NCT05958368 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The listed sponsor is Pennington Biomedical Research Center, which has 258 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Avocado is the first listed.

NCT05958368 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.

Frequently Asked Questions

What is clinical trial NCT05958368 about?

NCT05958368 is a clinical study titled "Assessing the Value of Avocados on Glycemic Control in Type 2 Diabetes". The objective of this study is to assess the effects of Hass Avocados on glycemic control. The investigators hypothesize that Hass Avocado consumption will reduce fasting blood sugar compared to an isocaloric amount of other fruit during controlled feeding.

What is the current status of trial NCT05958368?

This trial is currently recruiting. It is a NA study. The enrollment target is 48 participants. The study started on 2023-10-10. Estimated completion is 2026-12-15.

What conditions does trial NCT05958368 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Overweight and Obesity, Insulin, Glucose, Fructosamine.

What interventions are being tested in trial NCT05958368?

The interventions under investigation include: Avocado (OTHER), Other Fruit(s) (OTHER).

Who is sponsoring clinical trial NCT05958368?

This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05958368 being conducted?

This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.